Clinical trials: Healthy Male
Healthy
Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects
The objectives of this study are to evaluate the safety and tolerability; and to determine the effect of food on the pharmacokinetics (PK) of CHR-2797 in normal healthy male subjects.
- Trial name
- 8265134 (NCT01638442)
- Testing
- CHR-2797
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Healthy
Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers
The objective of the study is to assess that pramipexole does not prolong the QT interval more than placebo
- Trial name
- NCT02262546
- Testing
- Pramipexole extended-release (ER) tablets, Pramipexole immediate-release (IR) tablets, Moxifloxacin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Adult Male
Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg
To investigate the bioequivalence of brexpiprazole ODT 2 mg and brexpiprazole conventional tablet 2 mg
- Trial name
- NCT03902574
- Testing
- Brexpiprazole ODT 2mg with water, Brexpiprazole ODT 2mg without water, Brexpiprazole conventional tablet 2mg
- Where
- Japan
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy
A Study of 14C JNJ-67953964 in Healthy Adult Male Participants
The purpose of this study is to assess the pharmacokinetic (PK), metabolism, and routes of excretion of aticaprant and its metabolites in excreta and in plasma after a single oral dose 14C-aticaprant in healthy adult male…
- Trial name
- NCT05197062
- Testing
- 14C-aticaprant
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Male Subjects
A Drug-drug Interaction Study With TS-172 in Healthy Adult Male Subjects
An open-label, single-center, single-sequence study to evaluate the drug-drud interaction between the CYP3A substrate triazolam and TS-172 (part A) and the potent CYP3A inhibitor itraconazole and TS-172 (part B) in healthy male…
- Trial name
- NCT06837142
- Testing
- Triazolam and TS-172, TS-172 and itraconazole
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of SR exenatide (PT302) in healthy subjects.
- Trial name
- NCT00964262
- Testing
- SR Exenatide (PT302)
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Peptron, Inc.
Osteoporosis
Safety and Tolerability of Odanacatib (0822-059)
This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib
- Trial name
- NCT01068262
- Testing
- Odanacatib
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Bacterial Infections
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin
This is a 3-part, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of XNW4107 given as intravenous (IV) infusion in healthy male subjects.
- Trial name
- NCT04482569
- Testing
- XNW4107
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Evopoint Biosciences Inc.
Recurrent Genital Herpes Simplex Type 2
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
This study is designed to assess safety, tolerability, and pharmacokinetics (PK) of single ascending dose (SAD) of ABI-5366 in Part A in healthy participants and multiple-ascending doses (MAD) of ABI-5366 in Part B in…
- Trial name
- NCT06385327
- Testing
- ABI-5366
- Where
- 15 sites in Australia, New Zealand
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Healthy Volunteers - Haemophilia A
A Research Study of How a New Medicine NNC0365-3769 (Mim8) Works in the Body of Healthy People
NN0365-3769 (Mim8) is a study medicine with the potential to prevent and reduce bleeding in people with haemophilia A (an inherited disorder in which blood does not coagulate properly).
- Trial name
- NCT05127473
- Testing
- Mim8 B, 10 mg/mL, Mim8 B, 100 mg/mL
- Where
- 2 sites in Germany
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy
Single and Multiple Ascending Doses of AZD1981 in Japan
The purpose of this study is to study safety, tolerability and pharmacokinetics of AZD1981 in healthy Japanese subjects
- Trial name
- JSAD/JMAD (NCT00698282)
- Testing
- AZD1981
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Safety, Tolerability, PK, PD, ADA of Escalating Single Dose of CJ-40002 in Healthy Male Subjects
The objectives of this study are: To evaluate the safety and tolerability of CJ-40002 after single SC injection in healthy male volunteers. To evaluate the PK of CJ-40002 after single SC injection in healthy male volunteers.
- Trial name
- hGH (NCT02146625)
- Testing
- CJ-40002
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Healthy
Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Midazolam in Healthy Male Volunteers
The objective of the study was to investigate the effect of BIRT 2584 XX and its metabolite BI 610100 when BIRT 2584 XX is administered as a tablet to near steady state in estimated high therapeutic dose on the pharmacokinetics…
- Trial name
- NCT02256748
- Testing
- BIRT 2584 XX, Midazolam
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Safety, Tolerability, PD and PK Study in Healthy Adults
The primary objective of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of TRV734 given as a single dose (Part A) and as multiple ascending doses (Part B) in healthy subjects.
- Trial name
- NCT02211625
- Testing
- Open-label TRV734 125 mg, TRV734 blinded, Oxycodone IR 10 mg
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Trevena Inc.
Gouty Arthritis (GA)
A Bioequivalence Study of Two Different Dosage Form of Genakumab
The purpose of this study is to investigate whether Genakumab Injection is bioequivalent to Genakumab for Injection.
- Trial name
- NCT06451848
- Testing
- Genakumab Injection (T, Solution for injection), Genakumab for Injection (R, Powder for solution for injection)
- Where
- China
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Healthy
A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants
The main purpose of this study is to evaluate how much of the study drug (LY3372689), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air…
- Trial name
- NCT05749848
- Testing
- [¹⁴C]-LY3372689
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy, Renal Insufficiency
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants
The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired kidney function and healthy participants.
- Trial name
- NCT06190678
- Testing
- Pirtobrutinib
- Where
- 5 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity
A phase 1, randomized, double-blind, parallel group, single-dose study to compare the pharmacokinetics, pharmacodynamics, safety and immunogenicity of two formulations of Omalizumab (CMAB007 and Xolair) in healthy subjects.
- Trial name
- NCT05897008
- Testing
- CMAB007, Xolair
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Healthy
Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose in Healthy Male Subjects
food interaction, pharmacokinetics, safety and tolerability
- Trial name
- NCT02259985
- Testing
- Itasetron tablet, Itasetron infusion, high fat breakfast
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are Tolerated
The goal of this trial is to investigate safety, tolerability and pharmacokinetics of BI 1584862 in healthy male subjects of Japanese ethnicity following oral administration of single rising doses.
- Trial name
- NCT06148948
- Testing
- BI 1584862
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.